Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric ...
--Preclinical data for Cimeio’s CD45 universal heme ADC and shielded HSCs demonstrate effective depletion of an aggressive AML cell line in vivo-- --First data for Cimeio’s CD33 shielded HSCs show ...
CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD45 Shielded Cell & ...
Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric ...
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM). This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting ...
Because CD45 is found on nearly all blood cells -- and is usually highly expressed on blood cancer cells -- a treatment that wipes out all CD45-bearing cells would leave patients without any blood ...
CAR-T cell therapies have been heralded as a game changer for blood cancers, but those therapies approved so far have been focused on a few subtypes of leukemia, lymphoma and myeloma. Now, a new ...
CD45 + C1q + CCR8+ cells may serve as a biomarker for kidney disease severity and progression risk, reflecting inflammation and fibrosis. Elevated levels of these cells correlate with serum creatinine ...
A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer. Scientists in the Perelman School ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results